MACS
®
Marker Screen, human, version 02 has been designed for screening and analysis of 378 human markers by flow cytometry. Flow cytometry is an efficient tool for analyzing differential protein expression in heterogeneous cell populations, in sample cohorts, or in response to different culture and experimental conditions. The kit combines the benefits of flow cytometry and high quality pre-titrated antibodies to screen for markers of interest in a standardized and high throughput manner. Identified markers or combinations of markers can serve to better characterize cell compositions or cells of interests, e.g., for quality

Specifications for
MACS
®
Marker Screen, human, version 02

Overview

MACS
®
Marker Screen, human, version 02 has been designed for screening and analysis of 378 human markers by flow cytometry. Flow cytometry is an efficient tool for analyzing differential protein expression in heterogeneous cell populations, in sample cohorts, or in response to different culture and experimental conditions. The kit combines the benefits of flow cytometry and high quality pre-titrated antibodies to screen for markers of interest in a standardized and high throughput manner. Identified markers or combinations of markers can serve to better characterize cell compositions or cells of interests, e.g., for quality control purposes. Furthermore, markers can be utilized to develop target cell isolation strategies.

Detailed product information

MACS
®
Marker Screen, human, version 02 contains 378 APC-conjugated monoclonal antibodies specific to cell surface markers, and six isotype control antibodies arrayed onto four 96-well plates. The kit offers an array of pre-titrated, high quality antibodies, validated for flow cytometry analysis.
Predefined experiment tables containing well annotations and basic instrument settings for MACSQuant
®
Instruments (see Library tab) allow for convenient annotation and analysis of samples.
The updated “version 02” offers improved performance and an advanced and revised marker selection, containing predominantly our REAfinity™ Recombinant Antibodies. REAfinity Antibodies are generated in a biologically and chemically defined
in vitro
expression system to guarantee maximum purity and lot-to-lot consistency. The genetic sequence is engineered to lack binding to Fcγ receptors (FcγRs). Binding to FcγRs is one of the main causes of background signal in flow cytometry analysis. In addition, use of APC-conjugated antibodies in MACS Marker Screen, human, version 02 allows for convenient screening of GFP- or YFP-expressing cells.

Applications

MACS Marker Screen, human, version 02 has been developed for standardized, flow cytometry–based high throughput screening of surface marker expression for:
  • Characterization or profiling of cell lines or primary cells and cell mixtures
  • Development of cell separation strategies
  • Identification of expression changes with different experimental conditions, e.g., upon cytokine stimulation, co-cultivation, differentiation, variation of cultivation media, etc.

References for
MACS
®
Marker Screen, human, version 02

Publications

  1. Bari, R. et al. (2019) A Distinct Subset of Highly Proliferative and Lentiviral Vector (LV)-Transducible NK Cells Define a Readily Engineered Subset for Adoptive Cellular Therapy. Front Immunol 10: 2001
  2. Schwane, V. et al. (2020) Distinct Signatures in the Receptor Repertoire Discriminate CD56bright and CD56dim Natural Killer Cells. Front Immunol 11: 568927
  3. Lehnen, D. et al. (2017) IAP-Based Cell Sorting Results in Homogeneous Transplantable Dopaminergic Precursor Cells Derived from Human Pluripotent Stem Cells Stem Cell Reports 9(4): 1207-1220
  4. Schäfer, D. et al. (2021) Identification of CD318, TSPAN8 and CD66c as target candidates for CAR T cell based immunotherapy of pancreatic adenocarcinoma. Nat Commun. 12: 1453